Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The evolution of adaptiveness: balancing speed and evidence

Nature Reviews Drug Discovery volume 17, pages 845–846 (2018)Cite this article

Subjects

'Adaptive' approaches to bringing drugs to market have been widely discussed in recent years. Here, we describe the evolution of the adaptive approach and of concepts developed by ADAPT SMART, a multi-stakeholder consortium funded by the European Innovative Medicines Initiative.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Eichler, H.-G. et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91, 426–437 (2012).

    Article  Google Scholar 

  2. Djulbegovic, B. et al. Larger effect sizes in non-randomized studies are associated with higher rates of EMA licensing approval. J. Clin. Epidemiol. 98, 24–32 (2018)10.1016/j.jclinepi.2018.01.011.

    Article  PubMed  Google Scholar 

  3. Bouvy, J. C. et al. Managed entry for pharmaceuticals in the context of adaptive pathways in Europe. Front. Pharmacol. 9, 280 (2018)10.3389/fphar.2018.00280.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The views in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the agencies or organizations with which the authors are affiliated.

Author information

Authors and Affiliations

  1. European Medicines Agency (EMA), London, UK

    Hans-Georg Eichler & Francesca Cerreta

  2. Centre for the Advancement of Sustainable Medical Innovation (CASMI), Oxford, UK

    Richard Barker

  3. European Patients Forum (EPF), Brussels, Belgium

    Nicola Bedlington

  4. National Institute for Health and Care Excellence (NICE), London, UK

    Jacoline C. Bouvy

  5. Lygature, Utrecht, Netherlands

    André W. Broekmans

  6. Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA), Vienna, Austria

    Anna Bucsics

  7. AstraZeneca, Paris, France

    Solange Corriol-Rohou

  8. Sanofi, Barcelona, Catalunya, Spain

    Alicia Granados

  9. EURORDIS, Paris, France

    Yann Le Cam

  10. National Health Care Institute (ZIN), Diemen, Netherlands

    Ad Schuurman

Authors
  1. Hans-Georg Eichler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Barker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicola Bedlington
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jacoline C. Bouvy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. André W. Broekmans
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anna Bucsics
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francesca Cerreta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Solange Corriol-Rohou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Alicia Granados
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yann Le Cam
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ad Schuurman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Georg Eichler.

Ethics declarations

Competing interests

Richard Barker is a non-executive director of Image Analysis Group, Kvatchii and Celgene. Solange Corriol-Rohou is an employee of AstraZeneca. Alicia Granados is an employee of Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eichler, HG., Barker, R., Bedlington, N. et al. The evolution of adaptiveness: balancing speed and evidence. Nat Rev Drug Discov 17, 845–846 (2018). https://doi.org/10.1038/nrd.2018.90

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.90

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research